[Form 4] Charles River Laboratories International, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Charles River Laboratories EVP Joseph W. LaPlume reported a sale of 400 shares of common stock on 08/07/2025 at $150.04 per share. After the transaction he directly owned 24,916 shares. The filing is a routine Form 4 disclosure recording an officer's change in beneficial ownership and shows no derivative transactions.

Insights

Securities Analyst

TL;DR: Small officer sale; limited market impact given remaining direct holdings.

The Form 4 reports a direct sale of 400 common shares at $150.04, leaving the reporting person with 24,916 shares. Table II lists no derivative activity, so this is a straightforward non-derivative disposition. From a trading-impact perspective the transaction size is modest and the disclosure meets Section 16 reporting requirements.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16 rules; transaction appears routine for an officer.

Joseph W. LaPlume is identified as an officer (EVP, Corporate Strategy & Development) and the Form 4 records the sale and post-transaction direct ownership. The filing includes a manual signature and an explanation section but contains no indication of a 10b5-1 plan or related derivative transactions in Table II.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaPlume Joseph W

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corp Strategy & Develop

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		S		400	D	$150.04	24,916	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Joseph W. LaPlume	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Charles River (CRL) insider Joseph LaPlume report on Form 4?

He reported a sale of 400 shares of common stock on 08/07/2025 at $150.04 per share, with 24,916 shares owned after the sale.

What is Joseph W. LaPlume's role at Charles River (CRL)?

He is listed as an officer with the title EVP, Corporate Strategy & Development and the filing shows direct beneficial ownership.

Does the Form 4 show any derivative transactions for CRL?

No. Table II for derivative securities is empty, indicating no derivative transactions were reported on this Form 4.

How many shares did LaPlume own after the reported transaction?

After the reported sale he directly owned 24,916 shares of Charles River common stock.

Was the sale reported on Form 4 large relative to the reporting person's holdings?

The sale was 400 shares, which is small compared with the 24,916 shares reported as owned after the transaction.